These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

863 related items for PubMed ID: 11802586

  • 21. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M, Bate A.
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL.
    J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL.
    Arch Intern Med; 2006 Oct 09; 166(18):1938-42. PubMed ID: 17030825
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA.
    Mol Ther; 2005 Dec 09; 12(6):991-2. PubMed ID: 16271514
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
    Hauben M, Reich L, Chung S.
    Eur J Clin Pharmacol; 2004 Dec 09; 60(10):747-50. PubMed ID: 15619136
    [Abstract] [Full Text] [Related]

  • 35. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
    Weaver J, Grenade LL, Kwon H, Avigan M.
    Dermatol Ther; 2009 Dec 09; 22(3):204-15. PubMed ID: 19453344
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. MedWatch: the FDA medical products reporting program.
    Rheinstein PH.
    Am Fam Physician; 1993 Sep 15; 48(4):636-8. PubMed ID: 8379493
    [No Abstract] [Full Text] [Related]

  • 38. The Vaccine Safety Datalink project.
    DeStefano F, Vaccine Safety Datalink Research Group.
    Pharmacoepidemiol Drug Saf; 2001 Sep 15; 10(5):403-6. PubMed ID: 11802585
    [Abstract] [Full Text] [Related]

  • 39. Postmarketing surveillance.
    Oleen MA.
    Can J Hosp Pharm; 1987 Oct 15; 40(5):171-2, 179-80. PubMed ID: 10284449
    [Abstract] [Full Text] [Related]

  • 40. Safety in numbers--monitoring risk in approved drugs.
    Okie S.
    N Engl J Med; 2005 Mar 24; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.